{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:52:03Z","timestamp":1771476723679,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00345-019-02818-3","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T16:02:38Z","timestamp":1559750558000},"page":"269-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond"],"prefix":"10.1007","volume":"38","author":[{"given":"Steven A.","family":"Mills","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin K.","family":"Gelbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,5]]},"reference":[{"key":"2818_CR1","volume-title":"Early Greek astronomy to Aristotle","author":"D Dicks","year":"1985","unstructured":"Dicks D (1985) Early Greek astronomy to Aristotle. Cornell University Press, Ithaca"},{"key":"2818_CR2","volume-title":"The voyage of Magellan","author":"A Pigafetta","year":"1969","unstructured":"Pigafetta A, Paige P (1969) The voyage of Magellan. Prentice-Hall, Englewood Cliffs"},{"key":"2818_CR3","first-page":"1","volume-title":"Peyronie\u2019s disease: a guide to clinical management","author":"E Akkus","year":"2007","unstructured":"Akkus E (2007) Historical review of Peyronie\u2019s disease: de la Peyronie to Devine. In: Levine LA (ed) Peyronie\u2019s disease: a guide to clinical management. Humana Press, Totowa, pp 1\u20138"},{"issue":"1","key":"2818_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.21037\/tau.2016.11.01","volume":"6","author":"J Campbell","year":"2017","unstructured":"Campbell J, Alzubaidi R (2017) Understanding the cellular basis and pathophysiology of Peyronie\u2019s disease to optimize treatment for erectile dysfunction. Transl Androl Urol 6(1):46\u201359","journal-title":"Transl Androl Urol"},{"issue":"Suppl 5","key":"2818_CR5","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1038\/sj.ijir.3901082","volume":"15","author":"JP Mulhall","year":"2003","unstructured":"Mulhall JP (2003) Expanding the paradigm for plaque development in Peyronie\u2019s disease. Int J Impot Res 15(Suppl 5):S93\u2013S102","journal-title":"Int J Impot Res"},{"issue":"5","key":"2818_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/S0090-4295(97)00333-6","volume":"50","author":"D Schiavino","year":"1997","unstructured":"Schiavino D, Sasso F, Nucera E et al (1997) Immunologic findings in Peyronie\u2019s disease: a controlled study. Urology 50(5):764\u2013768","journal-title":"Urology"},{"issue":"12","key":"2818_CR7","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1172\/JCI102861","volume":"32","author":"I Mandl","year":"1953","unstructured":"Mandl I, Maclennan JD, Howes EL (1953) Isolation and characterization of proteinase and collagenase from Cl. histolyticum. J Clin Investig 32(12):1323\u20131329","journal-title":"J Clin Investig"},{"issue":"4443","key":"2818_CR8","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/1741191a0","volume":"174","author":"R Debellis","year":"1954","unstructured":"Debellis R, Mandl I, Maclennan JD, Howes EL (1954) Separation of proteolytic enzymes of Clostridium histolyticum. Nature 174(4443):1191\u20131192","journal-title":"Nature"},{"key":"2818_CR9","first-page":"116","volume":"1","author":"KA Mookhtiar","year":"1992","unstructured":"Mookhtiar KA, Van Wart HE (1992) Clostridium histolyticum collagenases: a new look at some old enzymes. Matrix Suppl 1:116\u2013126","journal-title":"Matrix Suppl"},{"issue":"3","key":"2818_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1021\/bi00377a004","volume":"26","author":"MF French","year":"1987","unstructured":"French MF, Mookhtiar KA, Van Wart HE (1987) Limited proteolysis of type I collagen at hyperreactive sites by class I and II Clostridium histolyticum collagenases: complementary digestion patterns. Biochemistry 26(3):681\u2013687","journal-title":"Biochemistry"},{"issue":"9","key":"2818_CR11","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1016\/j.transproceed.2011.09.059","volume":"43","author":"AG Breite","year":"2011","unstructured":"Breite AG, Mccarthy RC, Dwulet FE (2011) Characterization and functional assessment of Clostridium histolyticum class I (C1) collagenases and the synergistic degradation of native collagen in enzyme mixtures containing class II (C2) collagenase. Transpl Proc 43(9):3171\u20133175","journal-title":"Transpl Proc"},{"key":"2818_CR12","first-page":"1","volume-title":"Collagenase","author":"I Mandl","year":"1972","unstructured":"Mandl I (1972) Collagenase comes of age. In: Mandl I (ed) Collagenase. Gordon and Breach Science Publishers, New York, pp 1\u201316"},{"key":"2818_CR13","first-page":"101","volume-title":"collagenase","author":"BJ Sussman","year":"1972","unstructured":"Sussman BJ, Mann M (1972) Experimental intervertebral discolysis with collagenase. In: Mandl I (ed) collagenase. Gordon and Breach Science Publishers, New York, pp 101\u2013112"},{"key":"2818_CR14","first-page":"123","volume-title":"collagenase","author":"EL Howes","year":"1972","unstructured":"Howes EL (1972) Early investigations of the treatment of third degrees burns with collagenase. In: Mandl I (ed) collagenase. Gordon and Breach Science Publishers, New York, pp 123\u2013130"},{"key":"2818_CR15","first-page":"1","volume-title":"collagenase","author":"WE Zimmerman","year":"1972","unstructured":"Zimmerman WE (1972) The importance of collagenase for the local treatment of major burns. In: Mandl I (ed) collagenase. Gordon and Breach Science Publishers, New York, pp 1\u201316"},{"key":"2818_CR16","first-page":"177","volume":"109","author":"EL Howes","year":"1959","unstructured":"Howes EL, Mandl I, Zarruto S, Akerman W (1959) The use of Clostridium histolyticum enzymes in the treatment of experimental third-degree burns. Surg Gynecol Obstet 109:177\u2013188","journal-title":"Surg Gynecol Obstet"},{"issue":"5","key":"2818_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/00007632-198407000-00012","volume":"9","author":"JW Bromley","year":"1984","unstructured":"Bromley JW, Varma AO, Santoro AJ, Cohen P, Jacobs R, Berger L (1984) Double-blind evaluation of collagenase injections for herniated lumbar discs. Spine 9(5):486\u2013488","journal-title":"Spine"},{"issue":"6","key":"2818_CR18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/00007632-198507000-00010","volume":"10","author":"B Rydevik","year":"1985","unstructured":"Rydevik B, Brown MD, Ehira T, Nordborg C (1985) Effects of collagenase on nerve tissue. An experimental study on acute and long-term effects in rabbits. Spine 10(6):562\u2013566","journal-title":"Spine"},{"issue":"1","key":"2818_CR19","first-page":"17","volume":"23","author":"B Rydevik","year":"1989","unstructured":"Rydevik B, Ehira T, Linder L, Olmarker K, Romanus M, Br\u00e5nemark PI (1989) Microvascular response to locally injected collagenase. An experimental investigation in hamsters and rabbits. Scand J Plast Reconstr Surg Hand Surg 23(1):17\u201321","journal-title":"Scand J Plast Reconstr Surg Hand Surg"},{"issue":"6","key":"2818_CR20","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/jsm.12904","volume":"12","author":"MK Gelbard","year":"2015","unstructured":"Gelbard MK, Chagan L, Tursi JP (2015) Collagenase Clostridium histolyticum for the treatment of Peyronie\u2019s disease: the development of this novel pharmacologic approach. J Sex Med 12(6):1481\u20131489","journal-title":"J Sex Med"},{"issue":"9","key":"2818_CR21","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1517\/14712598.2010.510509","volume":"10","author":"SS Desai","year":"2010","unstructured":"Desai SS, Hentz VR (2010) Collagenase Clostridium histolyticum for Dupuytren\u2019s contracture. Expert Opin Biol Ther 10(9):1395\u20131404","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"2818_CR22","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.cardiores.2005.12.002","volume":"69","author":"H Nagase","year":"2006","unstructured":"Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69(3):562\u2013573","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2818_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/bip.10201","volume":"66","author":"JL Lauer-fields","year":"2002","unstructured":"Lauer-fields JL, Juska D, Fields GB (2002) Matrix metalloproteinases and collagen catabolism. Biopolymers 66(1):19\u201332","journal-title":"Biopolymers"},{"issue":"2","key":"2818_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1042\/bj1390359","volume":"139","author":"Z Werb","year":"1974","unstructured":"Werb Z, Burleigh MC, Barrett AJ, Starkey PM (1974) The interaction of alpha2-macroglobulin with proteinases Binding and inhibition of mammalian collagenases and other metal proteinases. Biochem J 139(2):359\u2013368","journal-title":"Biochem J"},{"issue":"12","key":"2818_CR25","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1111\/j.1743-6109.2008.01011.x","volume":"5","author":"M Gelbard","year":"2008","unstructured":"Gelbard M (2008) Myofibroblasts and mechanotransduction: do forces in the tunica albuginea contribute to Peyronie\u2019s disease? J Sex Med 5(12):2974\u20132976","journal-title":"J Sex Med"},{"issue":"5","key":"2818_CR26","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/0090-4295(80)90028-X","volume":"15","author":"M Gelbard","year":"1980","unstructured":"Gelbard M, Walsh R, Kaufman JJ (1980) Clostridial collagenase and Peyronie disease. Urology 15(5):536","journal-title":"Urology"},{"issue":"3","key":"2818_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF00255956","volume":"10","author":"MK Gelbard","year":"1982","unstructured":"Gelbard MK, Walsh R, Kaufman JJ (1982) Collagenase for Peyronie\u2019s disease experimental studies. Urol Res 10(3):135\u2013140","journal-title":"Urol Res"},{"issue":"Suppl 4","key":"2818_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0022-5347(09)60794-1","volume":"181","author":"M Del Carlo","year":"2009","unstructured":"Del Carlo M, Cole AA, Emeigh Hart SG, Levine LA (2009) Comparative analysis of collagen degradation in Peyronie\u2019s disease plaque and Dupuytren\u2019s contracture cord tissues injected with mixed collagenase subtypes. J Urol 181(Suppl 4):279","journal-title":"J Urol"},{"issue":"2","key":"2818_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S0022-5347(17)47123-0","volume":"134","author":"MK Gelbard","year":"1985","unstructured":"Gelbard MK, Lindner A, Kaufman JJ (1985) The use of collagenase in the treatment of Peyronie\u2019s disease. J Urol 134(2):280\u2013283","journal-title":"J Urol"},{"issue":"1","key":"2818_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","volume":"149","author":"MK Gelbard","year":"1993","unstructured":"Gelbard MK, James K, Riach P, Dorey F (1993) Collagenase versus placebo in the treatment of Peyronie\u2019s disease: a double-blind study. J Urol 149(1):56\u201358","journal-title":"J Urol"},{"issue":"1","key":"2818_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1743-6109.2007.00651.x","volume":"5","author":"GH Jordan","year":"2008","unstructured":"Jordan GH (2008) The use of intralesional clostridial collagenase injection therapy for Peyronie\u2019s disease: a prospective, single-center, non-placebo-controlled study. J Sex Med 5(1):180\u2013187","journal-title":"J Sex Med"},{"issue":"10","key":"2818_CR32","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1056\/NEJMoa0810866","volume":"361","author":"LC Hurst","year":"2009","unstructured":"Hurst LC, Badalamente MA, Hentz VR et al (2009) Injectable collagenase Clostridium histolyticum for Dupuytren\u2019s contracture. N Engl J Med 361(10):968\u2013979","journal-title":"N Engl J Med"},{"issue":"6","key":"2818_CR33","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","volume":"187","author":"M Gelbard","year":"2012","unstructured":"Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA (2012) Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol 187(6):2268\u20132274","journal-title":"J Urol"},{"issue":"1","key":"2818_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJ et al (2013) Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 190(1):199\u2013207","journal-title":"J Urol"},{"issue":"2","key":"2818_CR35","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/j.esxm.2017.02.001","volume":"5","author":"I Goldstein","year":"2017","unstructured":"Goldstein I, Knoll LD, Lipshultz LI, Smith T, Kaufman GJ, Mcmahon CG (2017) Changes in the effects of Peyronie\u2019s disease after treatment with collagenase Clostridium histolyticum: male patients and their female partners. Sex Med 5(2):e124\u2013e130","journal-title":"Sex Med"},{"key":"2818_CR36","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/JU.0000000000000032","volume":"201","author":"WJG Hellstrom","year":"2019","unstructured":"Hellstrom WJG, Tue Nguyen HM, Alzweri L et al (2019) Intralesional collagenase Clostridium histolyticum causes meaningful improvement in men with Peyronie\u2019s disease: results of a multi-institutional analysis. J Urol 201:777\u2013782","journal-title":"J Urol"},{"issue":"5","key":"2818_CR37","doi-asserted-by":"publisher","first-page":"894","DOI":"10.21037\/tau.2017.07.27","volume":"6","author":"L Diao","year":"2017","unstructured":"Diao L, Anaissie J, Nguyen HMT et al (2017) Effect of collagenase Clostridium histolyticum on penile vascular and morphological parameters in patients with Peyronie\u2019s disease. Transl Androl Urol 6(5):894\u2013898","journal-title":"Transl Androl Urol"},{"issue":"5","key":"2818_CR38","doi-asserted-by":"publisher","first-page":"888","DOI":"10.21037\/tau.2017.07.26","volume":"6","author":"HMT Nguyen","year":"2017","unstructured":"Nguyen HMT, Delay KJ, Diao L et al (2017) Racial variations in response to intralesional collagenase Clostridium histolyticum in men with Peyronie\u2019s disease. Transl Androl Urol 6(5):888\u2013893","journal-title":"Transl Androl Urol"},{"key":"2818_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","volume":"100","author":"J Anaissie","year":"2017","unstructured":"Anaissie J, Yafi FA, Delay KJ, Traore EJ, Sikka SC, Hellstrom WJG (2017) Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie\u2019s disease. Urology 100:125\u2013130","journal-title":"Urology"},{"issue":"5","key":"2818_CR40","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bju.13932","volume":"120","author":"A Abdel Raheem","year":"2017","unstructured":"Abdel Raheem A, Capece M, Kalejaiye O et al (2017) Safety and effectiveness of collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease using a new modified shortened protocol. BJU Int 120(5):717\u2013723","journal-title":"BJU Int"},{"issue":"4","key":"2818_CR41","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/andr.12497","volume":"6","author":"M Capece","year":"2018","unstructured":"Capece M, Cocci A, Russo G et al (2018) Collagenase Clostridium histolyticum for the treatment of Peyronie\u2019s disease: a prospective Italian multicentric study. Andrology 6(4):564\u2013567","journal-title":"Andrology"},{"key":"2818_CR42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.urology.2018.06.049","volume":"120","author":"FA Yafi","year":"2018","unstructured":"Yafi FA, Diao L, Delay KJ et al (2018) Multi-institutional prospective analysis of intralesional injection of collagenase Clostridium histolyticum, tunical plication, and partial plaque excision and grafting for the management of Peyronie\u2019s disease. Urology 120:138\u2013142","journal-title":"Urology"},{"key":"2818_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","volume":"94","author":"KK Yang","year":"2016","unstructured":"Yang KK, Bennett N (2016) Peyronie\u2019s disease and injectable collagenase Clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. Urology 94:143\u2013147","journal-title":"Urology"},{"key":"2818_CR44","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.urology.2017.01.054","volume":"104","author":"MJ Ziegelmann","year":"2017","unstructured":"Ziegelmann MJ, Viers BR, Montgomery BD, Avant RA, Savage JB, Trost LW (2017) Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie disease. Urology 104:102\u2013109","journal-title":"Urology"},{"issue":"1","key":"2818_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41443-018-0063-1","volume":"31","author":"PN Tsambarlis","year":"2019","unstructured":"Tsambarlis PN, Yong R, Levine LA (2019) Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie\u2019s disease. Int J Impot Res 31(1):15\u201319","journal-title":"Int J Impot Res"},{"issue":"2","key":"2818_CR46","doi-asserted-by":"publisher","first-page":"e0150157","DOI":"10.1371\/journal.pone.0150157","volume":"11","author":"M Stuntz","year":"2016","unstructured":"Stuntz M, Perlaky A, Des Vignes F, Kyriakides T, Glass D (2016) The prevalence of Peyronie\u2019s disease in the United States: a population-based study. PLoS One 11(2):e0150157","journal-title":"PLoS One"},{"key":"2818_CR47","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5534\/wjmh.180073","volume":"37","author":"AJ Sun","year":"2019","unstructured":"Sun AJ, Li S, Eisenberg ML (2019) The impact of Clostridium histolyticum collagenase on the prevalence and management of Peyronie\u2019s disease in the United States. World J Mens Health 37:234\u2013239","journal-title":"World J Mens Health"},{"issue":"2","key":"2818_CR48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jsxm.2018.12.011","volume":"16","author":"GI Russo","year":"2019","unstructured":"Russo GI, Cacciamani G, Cocci A et al (2019) Comparative effectiveness of intralesional therapy for Peyronie\u2019s disease in controlled clinical studies: a systematic review and network meta-analysis. J Sex Med 16(2):289\u2013299","journal-title":"J Sex Med"},{"key":"2818_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","volume":"119","author":"K Wymer","year":"2018","unstructured":"Wymer K, Ziegelmann M, Savage J, Kohler T, Trost L (2018) Plaque calcification: an important predictor of collagenase Clostridium histolyticum treatment outcomes for men with Peyronie\u2019s disease. Urology 119:109\u2013114","journal-title":"Urology"},{"issue":"3","key":"2818_CR50","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","volume":"194","author":"A Nehra","year":"2015","unstructured":"Nehra A, Alterowitz R, Culkin DJ et al (2015) Peyronie\u2019s disease: AUA guideline. J Urol 194(3):745\u2013753","journal-title":"J Urol"},{"issue":"10","key":"2818_CR51","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","volume":"14","author":"HMT Nguyen","year":"2017","unstructured":"Nguyen HMT, Anaissie J, Delay KJ, Yafi FA, Sikka SC, Hellstrom WJG (2017) Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie\u2019s disease. J Sex Med 14(10):1220\u20131225","journal-title":"J Sex Med"},{"issue":"1","key":"2818_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.sxmr.2017.03.005","volume":"6","author":"AT Gabrielson","year":"2018","unstructured":"Gabrielson AT, Spitz JT, Hellstrom WJG (2018) Collagenase Clostridium histolyticum in the treatment of urologic disease: current and future impact. Sex Med Rev 6(1):143\u2013156","journal-title":"Sex Med Rev"},{"issue":"5","key":"2818_CR53","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.jsxm.2016.02.122","volume":"13","author":"D Milam","year":"2016","unstructured":"Milam D (2016) 116 positive results with collagenase Clostridium histolyticum treatment in two patients with ventral penile curvature due to Peyronie\u2019s disease. J Sex Med 13(5):S55","journal-title":"J Sex Med"},{"issue":"3","key":"2818_CR54","doi-asserted-by":"publisher","first-page":"647.e1\u20136","DOI":"10.1016\/j.urology.2015.06.013","volume":"86","author":"P Sangkum","year":"2015","unstructured":"Sangkum P, Yafi FA, Kim H et al (2015) Collagenase Clostridium histolyticum (Xiaflex) for the treatment of urethral stricture disease in a rat model of urethral fibrosis. Urology 86(3):647.e1\u20136","journal-title":"Urology"},{"issue":"10","key":"2818_CR55","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jsxm.2018.08.012","volume":"15","author":"A Cocci","year":"2018","unstructured":"Cocci A, Cito G, Urz\u00ec D et al (2018) Sildenafil 25\u00a0mg ODT\u2009+\u2009collagenase Clostridium histolyticum vs collagenase Clostridium histolyticum alone for the management of Peyronie\u2019s disease: a matched-pair comparison analysis. J Sex Med 15(10):1472\u20131477","journal-title":"J Sex Med"},{"key":"2818_CR56","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.actbio.2018.05.007","volume":"74","author":"MR Villegas","year":"2018","unstructured":"Villegas MR, Baeza A, Usategui A, Ortiz-romero PL, Pablos JL, Vallet-reg\u00ed M (2018) Collagenase nanocapsules: an approach to fibrosis treatment. Acta Biomater 74:430\u2013438","journal-title":"Acta Biomater"},{"key":"2818_CR57","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41585-018-0117-7","volume":"16","author":"P Tsambarlis","year":"2019","unstructured":"Tsambarlis P, Levine LA (2019) Nonsurgical management of Peyronie\u2019s disease. Nat Rev Urol 16:172\u2013186","journal-title":"Nat Rev Urol"},{"issue":"2","key":"2818_CR58","first-page":"e26949","volume":"4","author":"A Nenna","year":"2015","unstructured":"Nenna A, Nappi F, Avtaar Singh SS et al (2015) Pharmacologic approaches against advanced glycation end products (AGEs) in diabetic cardiovascular disease. Res Cardiovasc Med 4(2):e26949","journal-title":"Res Cardiovasc Med"},{"key":"2818_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.matbio.2016.09.001","volume":"59","author":"A Gautieri","year":"2017","unstructured":"Gautieri A, Passini FS, Silv\u00e1n U et al (2017) Advanced glycation end-products: mechanics of aged collagen from molecule to tissue. Matrix Biol 59:95\u2013108","journal-title":"Matrix Biol"},{"issue":"6","key":"2818_CR60","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0090-4295(97)00512-8","volume":"50","author":"AD Seftel","year":"1997","unstructured":"Seftel AD, Vaziri ND, Ni Z et al (1997) Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 50(6):1016\u20131026","journal-title":"Urology"},{"issue":"11","key":"2818_CR61","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.jsxm.2017.08.015","volume":"14","author":"DJ Ralph","year":"2017","unstructured":"Ralph DJ, Abdel Raheem A, Liu G (2017) Treatment of Peyronie\u2019s disease with collagenase Clostridium histolyticum and vacuum therapy: a randomized, open-label pilot study. J Sex Med 14(11):1430\u20131437","journal-title":"J Sex Med"},{"key":"2818_CR62","unstructured":"(2013) Product Information: XIAFLEX(R) intralesional injection solution, collagenase Clostridium histolyticum intralesional injection solution. Auxilium Pharmaceuticals, Inc. (per manufacturer), Chesterbrook"},{"issue":"4","key":"2818_CR63","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bju.13096","volume":"116","author":"LI Lipshultz","year":"2015","unstructured":"Lipshultz LI, Goldstein I, Seftel AD et al (2015) Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int 116(4):650\u2013656","journal-title":"BJU Int"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02818-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-019-02818-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02818-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T23:17:53Z","timestamp":1591226273000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-019-02818-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,5]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2818"],"URL":"https:\/\/doi.org\/10.1007\/s00345-019-02818-3","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,5]]},"assertion":[{"value":"2 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MK Gelbard is on the speaker\u2019s bureau for Endo Pharmaceuticals Inc. and is a consultant for Biospecifics Technologies Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}